Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00749021 · ClinicalTrials.gov registry record · Phase 1
Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments
A Phase 1 study of Retinal Pigment Epithelial Detachment, sponsored by Clement K. Chan.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT00749021 is a Phase 1 study of Retinal Pigment Epithelial Detachment that has completed, run by Clement K. Chan. The registered enrollment target is 40 participants. The trial reports 3 study locations across 2 states.
The verdict
NCT00749021, a Phase 1 study of Retinal Pigment Epithelial Detachment, has completed, sponsored by Clement K. Chan.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
Conditions Studied
Interventions
- DRUG Ranibizumab
Study Locations (3)
California
- Jules Stein Eye Institute - Los Angeles
- Southern California Desert Retina Consultants - Palm Desert
South Dakota
- Black Hills Regional Eye Institute - Rapid City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00749021
The ClinicalTrials.gov registry entry for NCT00749021 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Clement K. Chan, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Retinal Pigment Epithelial Detachment appearing as the primary indexed condition, and to 1 intervention - of which Ranibizumab is the first listed.
NCT00749021 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, South Dakota.
Frequently Asked Questions
What is clinical trial NCT00749021 about?
NCT00749021 is a clinical study titled "Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments". This is a multicenter, randomized, open-label study. 40 patients will be followed for a period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg of intravitreal ranibizumab injection.
What is the current status of trial NCT00749021?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2012-08.
What conditions does trial NCT00749021 study?
This clinical trial studies the following conditions: Retinal Pigment Epithelial Detachment.
What interventions are being tested in trial NCT00749021?
The interventions under investigation include: Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT00749021?
This trial is sponsored by Clement K. Chan, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00749021 being conducted?
This trial has 3 study locations across California, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.